Literature DB >> 11961070

Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions.

Sharon R Grady1, Karen L Murphy, Jian Cao, Michael J Marks, J Michael McIntosh, Allan C Collins.   

Abstract

The inhibition of uptake of [(3)H]dopamine into synaptosomes prepared from four mouse brain regions was investigated. The inhibition curves demonstrated that in three regions, striatum, nucleus accumbens, and olfactory tubercle, [(3)H]dopamine was taken up exclusively by dopaminergic terminals. In frontal cortex, however, only a portion of the uptake was into dopaminergic terminals, with a larger amount taken up by noradrenergic terminals, and another small portion by serotonergic terminals. Release studies in frontal cortex indicated that in this region only dopaminergic and noradrenergic terminals are capable of packaging [(3)H]dopamine in a form allowing vesicle-mediated release; additionally, only the dopaminergic terminals have functional presynaptic nAChRs that, when stimulated by nicotinic agonists, evoke [(3)H]dopamine release. Agonist-stimulated [(3)H]dopamine release was characterized from synaptosomes prepared from four mouse brain regions. alpha-Conotoxin MII was a partial inhibitor of dopamine release in all of the brain regions, which suggests that a minimum of two nicotinic cholinergic receptors (nAChRs) are expressed in the nerve terminals of all four brain regions. No nicotine-induced [(3)H]dopamine release was detected in any brain region when the synaptosomes were prepared from beta2 null mutant mice, which indicates that the beta2 subunit is required for all nAChRs mediating this release. Dose-response curves were constructed for seven agonists in each of the brain regions. The pharmacological properties of synaptosomal [(3)H]dopamine release appear similar across the four brain regions. The results suggest that all four regions express the same nAChRs, although subtle regional differences may exist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961070     DOI: 10.1124/jpet.301.2.651

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  51 in total

1.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

2.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

Review 3.  Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.

Authors:  R Exley; S J Cragg
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

4.  Chronic nicotine alters nicotinic receptor-induced presynaptic Ca2+ responses in isolated nerve terminals.

Authors:  John J Dougherty; Jianlin Wu; Tejal K Mehta; Brett Brown; Robert A Nichols
Journal:  Neurochem Res       Date:  2007-12-20       Impact factor: 3.996

5.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

Review 6.  Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits.

Authors:  Huibert D Mansvelder; Marjolijn Mertz; Lorna W Role
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

Review 7.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

Review 8.  Pharmacotherapy for smoking cessation: current advances and research topics.

Authors:  Tobias Raupach; Constant P van Schayck
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

9.  Nicotine is highly effective at producing desensitization of rat alpha4beta2 neuronal nicotinic receptors.

Authors:  K G Paradiso; Joe Henry Steinbach
Journal:  J Physiol       Date:  2003-10-10       Impact factor: 5.182

Review 10.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.